global head of oncology R&D at GSK. “We are particularly encouraged by the potential for belantamab mafodotin when combined with BorDex to address high unmet need in relapsed/refractory multiple ...

Hesham Abdullah, global head of oncology R&D at GSK, said the results “reinforce our belief in the potential for belantamab mafodotin used in combination to redefine the treatment of multiple ...

And GSK’s first-to-market Arexvy lived up to that expectation with $1.5 billion sales in its first year of commercialization. Related As RSV vaccine clash kicks off, GSK sues Pfizer for patent ...

Elizabeth Warren (D-Mass.) is asking a federal watchdog to investigate GSK for replacing a popular asthma inhaler with a so-called authorized generic at a much higher price in order to avoid ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other best ADR stocks. American Depositary Receipts (ADR) are US-listed securities that represent shares ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other most undervalued biotech stocks to invest in. On February 21, Jared Holz, Mizuho Securities ...

GSK’s share price has fallen a long way from its one-year high, which has only increased the major undervaluation I’d seen in the stock before that. When investing, your capital is at risk ...